ALLMedicine™ Acute Lymphoblastic Leukemia Center
Research & Reviews 6,068 results
https://doi.org/10.1016/j.clml.2021.08.003
Clinical Lymphoma, Myeloma & Leukemia; Short NJ, Kantarjian H et. al.
Sep 26th, 2021 - Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) was historically considered to be a very poor-risk subtype of ALL. However, with the introduction of highly potent BCR-ABL tyrosine kinase inhibitors (TKIs), Ph+ ALL can now b...
https://doi.org/10.1111/ejh.13711
European Journal of Haematology; Kristjánsdóttir ER, Toksvang LN et. al.
Sep 26th, 2021 - Explore patient adherence and physician compliance to protocol guidelines during maintenance therapy, including the association with survival in adults with acute lymphoblastic leukemia (ALL). Blood counts, aminotransferase levels and prescribed 6...
https://doi.org/10.1080/16078454.2021.1978763
Hematology (Amsterdam, Netherlands); Saleh M, Khalil M et. al.
Sep 24th, 2021 - Matrix metalloproteinases (MMPs) play a crucial role in cancer progression and metastasis, however their role in pediatric Acute lymphoblastic leukemia (ALL) is still unrevealed. The diagnostic, prognostic and predictive value of tissue inhibitor ...
https://doi.org/10.6004/jnccn.2021.0042
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.
Sep 23rd, 2021 - The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies fo...
https://doi.org/10.1038/s41467-021-25708-y 10.1200/JCO.2003.05.116 10.1056/NEJMoa1510795 10.1093/jnci/djr533 10.3109/0284186X.2013.862596 10.1016/S0140-6736(98)11079-6 10.1016/S0002-9440(10)65397-7 10.1097/nen.0b013e3181257190 10.1016/j.wneu.2014.12.009 10.1007/s10014-009-0258-8 10.1097/MPH.0b013e3181e51403 10.4103/0973-1482.31974 10.1007/s10014-017-0292-x 10.1586/ern.09.98 10.1007/s00381-006-0199-z 10.1007/s11060-008-9565-x 10.1200/JCO.1998.16.12.3761 10.1200/JCO.2009.26.7252 10.1038/nature26000 10.1038/nature13268 10.1016/j.ccell.2015.04.002 10.1016/j.cell.2016.01.015 10.1038/nrclinonc.2012.87 10.1016/S1470-2045(14)71206-9 10.1038/nrc3655 10.1038/ng.2936 10.1007/s00401-017-1710-1 10.1016/j.ccr.2012.08.024 10.1038/nm.4204 10.1038/ng.2682 10.1038/onc.2009.73 10.1038/s41467-017-00174-7 10.1111/bjh.13903 10.1016/j.ijrobp.2015.11.046 10.1016/j.ijrobp.2016.03.049 10.3109/0284186X.2015.1008648 10.1002/cncr.26148 10.1002/cncr.28907 10.3389/fonc.2020.00989 10.1088/0031-9155/54/8/002 10.1080/02841860510029833 10.1016/j.ijrobp.2004.12.040 10.1038/s41598-020-58134-z 10.1016/j.ejca.2016.06.009 10.1007/s00066-016-1005-9 10.1038/nature11284 10.1002/pbc.21530 10.1038/nature22973 10.1007/s00401-011-0922-z 10.1016/S1470-2045(15)00167-9 10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7 10.1097/01.jnen.0000205146.62081.29 10.1200/JCO.2014.58.3922 10.1159/000121218 10.1200/JCO.2006.06.8213 10.1007/s00401-018-1888-x 10.1007/s00401-018-1877-0 10.1007/s00401-018-1865-4 10.1007/s00401-015-1519-8 10.1038/ncomms10001 10.1371/journal.pcbi.1001138 10.1007/s00401-016-1569-6
Nature Communications; Deng MY, Sturm D et. al.
Sep 22nd, 2021 - Long-term complications such as radiation-induced second malignancies occur in a subset of patients following radiation-therapy, particularly relevant in pediatric patients due to the long follow-up period in case of survival. Radiation-induced gl...
Guidelines 3 results
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.
Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.
Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.
Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...
Drugs 111 results see all →
News 669 results
https://www.medscape.com/viewarticle/954149
Jul 2nd, 2021 - The US Food and Drug Administration (FDA) has approved a new version of asparaginase for use in children and adults who have developed hypersensitivity to asparaginase derived from Escherichia coli. The new product is Jazz Pharmaceutical's Rylaze ...
https://www.medscape.com/viewarticle/952355
Jun 3rd, 2021 - Data from a small retrospective study suggest that venetoclax-based regimens may have activity against relapsed or refractory T-lineage acute lymphoblastic leukemia (T-ALL) in children and young adults. Among seven patients with T-ALL treated with...
https://www.medscape.com/viewarticle/951639
May 21st, 2021 - Even in the age of intensive therapy and extensive risk stratification, there are small but significant differences in outcomes between boys and girls with B-lineage acute lymphoblastic leukemia (B-ALL). This finding comes from a review of 10 year...
https://www.medscape.com/viewarticle/948896
Apr 7th, 2021 - Children and adolescents with leukemia who were placed on a restrictive diet and exercise regimen concurrent with starting chemotherapy showed responses to treatment that were better than those historically seen in such patients. This apparently i...
https://www.medscape.com/viewarticle/948153
Mar 25th, 2021 - The use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival in minimal residual disease (MRD)-negative remission patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) after the start...
